Business Wire

TIS and IDEMIA Join Forces to Provide Biometric Digital Identity Solutions for Financial Institutions, Using IDEMIA’s Digital Identity Platform for Research and Development

Share

Going forward, the two companies aim to conduct verification testing in Japan throughout 2018 targeted at financial institutions such as banks and credit card companies, amongst others, through joint research and development of highly secure and reliable biometric digital identity solutions based on IDEMIA’s digital identity and payment platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180531005666/en/

(Photo: IDEMIA)

(Photo: IDEMIA)

Biometric digital identity solutions for financial institutions are solutions that support the utilization of digital identity technologies, including biometric authentication, identity verification, and digital signatures. The incorporation of advanced digital identity technologies will enable the development of secure and convenient services for end users.

TIS has developed the brand-name of “PAYCIERGE”, based on its rich experience with development of critical systems for credit card companies and cutting-edge technologies. It has developed a broad range of services, from business systems that perform debit and prepaid card processing to mobile solutions in close proximity to the consumer for enhancing user convenience.

IDEMIA is the global leader in the fields of biometrics (fingerprint, facial and iris authentication), digital identity, and payment solutions. It has dozens of years of expertise worldwide, across the entire value chain in the field of Augmented Identity and provides numerous public and private markets with the most exhaustive digital trust suite (identity-verification technologies, risk-based authentication, Omni-channel online contracts, digital payments, etc.).

TIS and IDEMIA are now aiming to blend the two companies’ technologies to offer highly reliable and convenient mobile-based biometric digital identity solutions for financial institutions such as banks and credit card companies.

The following outline some of its uses:

  • Enabling the opening of a bank account within just a few minutes from a remote location while maintaining regulatory (KYC*, AML*, etc.) compliance.
  • Using facial authentication for secure access and performing highly-sensitive transactions (funds transfers and online payments).
  • Enabling enrolment anytime, anywhere, and on any device in any type of financial product (loans, savings, life insurance, etc.) in a legally-compliant form.

TIS has been developing the new concept “PAYCIERGE 2.0” since 2016, which is adapted to the needs of the ever-evolving payments business market and offering the new solutions to this market. The linkage of the biometric authentication technology and services of IDEMIA with the financial industry experience and technologies acquired by TIS will increase the value of services in the consumer domain and create a variety of payment services with high levels of security and usability.

Pierre Barrial, Executive Vice-President of IDEMIA’s Financial Institutions Business Unit, made the following comments with respect to this joint research: “I am proud of our partnership with TIS. By combining IDEMIA’s best-in-class knowledge in ID integration and TIS’s outstanding IS integration, we can create superior value-added services for Japanese financial institutions, acquire new customers, speed up market entry, and reduce integration costs.”

Kiyotaka Nakamura, TIS Managing Executive Officer and Division Manager of the Payment Services Division of the Service Strategy Sector, made the following comments: “I am very happy that we were able to announce the research and development efforts with IDEMIA, the global leader in Augmented Identity. TIS has been developing “PAYCIERGE” solutions, but the importance of security and usability has become clear with recent progress in FinTech. We will see business innovation and market creation in the payments domain utilizing the experience and technologies acquired by TIS and the security technologies and high-usability solutions of IDEMIA.”

*KYC: Know Your Customer
*AML: Anti-Money Laundering

About PAYCIERGE

TIS retail payments solution, “PAYCIERGE”, is the comprehensive brand for retail payment solutions that provide very convenient, secure mechanisms to all customers who need to make retail payments. “PAYCIERGE 2.0” is a new concept adapted to the needs of the ever-evolving payments business market. It helps broadly with business success by incorporating reliable systems and secure operations that leverage the advanced technologies, which have an overwhelming market share in the credit card industry, and rich know-how of TIS under the theme of “connections”, which includes strengthening “connections” by making alliances, strengthening “connections” with an open API platform, and developing overseas markets.

For more details, please refer to the following URL:
https://www.tis.jp/service_solution/paycierge/

About TIS

TIS of TIS INTEC Group offers a variety of service-oriented IT solutions, such as data centers and cloud IT solutions in addition to SI and commissioned development. At the same time, it has a global support system centralized in the China and ASEAN region, which supports more than 3000 business partners in various industries such as finance, manufacturing, distribution/service, public sector, and communications to contribute to the growth of our customers’ businesses.

For more details, please refer to the following URL:
http://www.tis.com

About IDEMIA

OT-Morpho is now IDEMIA, the global leader in Augmented Identity, with the ambition to empower citizens and consumers alike to interact, pay, connect, travel, and vote in ways that are now possible in a connected environment.
Securing our identities has become mission critical in the world we live in today. By standing for Augmented Identity, we reinvent the way we think, produce, use and protect this asset, whether for individuals or for objects. We ensure privacy and trust as well as guarantee secure, authenticated and verifiable transactions for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
OT (Oberthur Technologies) and Safran Identity & Security (Morpho) have joined forces to form IDEMIA. With close to $3 billion in revenue and 14,000 employees around the world, IDEMIA serves clients in 180 countries.

For more details, please refer to www.idemia.com. Follow them on Twitter at @IdemiaGroup.

Contact information

Press :
IDEMIA
Hanna Sebbah
HAVAS PARIS PR Agency
idemia@havas.com
or
TIS Inc.
Corporate Planning SBU
Corporate Communication Department
tis_pr@ml.tis.co.jp
or
Details for inquiries:
TIS Inc.
Service Strategy Secto
Payment Services Division
or
PAYCIERGE general contact
paycierge@ml.tis.co.jp

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gain Therapeutics SA Announces Award Notification of a €1.4M Grant Support From Eurostars-2 Together With the Institute for Research in Biomedicine and Neuro-Sys SAS After Having Scored 2nd Among 325 Eligible Applications23.7.2019 06:30:00 CESTPress release

Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in central nervous system (CNS) diseases, today announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Università della Svizzera italiana (USI) and Neuro-Sys SAS in Gardanne (France), it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency. This grant will further strengthen Gain Therapeutics’s novel therapeutic approach for targeting rare diseases in the CNS, where lysosomal misfolded enzymes lead to sever clinical phenotypes, where no treatment is available and/or high unmet medical needs still do afflict patients, families and carers. This funding will support the development of the drugs portfolio of Gain Therapeutics for the

iBASIS Accelerates Growth With JC Geha as Chief Operating Officer23.7.2019 06:00:00 CESTPress release

iBASIS, provider of communications solutions for operators and digital players worldwide, today announced the appointment of JC Geha as its COO. He will take his new post effective August 1, and be based at iBASIS’ headquarters in Lexington, Massachusetts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005757/en/ JC Geha (Photo: Business Wire) Formerly Senior Vice President, Head of International Technology and Services for Deutsche Telekom, and of Managed Services for Ericsson, Geha brings to iBASIS an impressive track record of profitable growth, technology and digital transformation expertise. His expertise spans 25 years of deep global industry relationships across the United States, Europe, Middle East, and Africa. Geha will lead iBASIS’ global operations, engineering, IT, and product development. He will report to iBASIS’ CEO and founder of the Group Tofane Global, Alexandre Pébereau, with the responsibility of g

Abzena Announces Successful Technical Transfer of Synaffix GlycoConnect™ Antibody Drug Conjugate (ADC) Technology to Enable Use in Client Projects23.7.2019 06:00:00 CESTPress release

Abzena, the global partner research organization, announced it has successfully completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect™ (antibody conjugation) and HydraSpace™ (highly polar spacer). Familiarity with these Antibody-Drug Conjugate (ADC) technologies adds to Abzena’s leadership in process development and GMP manufacturing of ADC linkers and payloads. Abzena can now rapidly ramp up ADC projects using Synaffix technology with high scientific quality. Jonathan Goldman, MD, Abzena CEO added: “Abzena believes in patient first drug development. Our expertise and experience with Synaffix GlycoConnect™ and HydraSpace™ technology further advances our leadership across multiple platforms in ADC. We look forward to supporting our customers as they leverage Synaffix technology to rapidly advance ADCs from IND stage into early clinical development.” About Abzena Abzena provides the most complete set of solutions in integrated discover

Aroma Bit to Develop Smartphone Embeddable Ultra-compact Silicon CMOS Based Smell Sensor That Has Dog Nose Equivalent Resolution in 1mm Squared Die Size23.7.2019 01:30:00 CESTPress release

Aroma Bit launched a new subsidiary to develop the next generation smell sensor based on silicon CMOS sensor substrate that are ultra-compact, high resolution and low cost. The technology is realized by applying Aroma Bit developed smell sensor receptor membrane technology to ultra-sensitive silicon CMOS based ion imaging sensor technology developed by professor Kazuaki Sawada at Toyohashi University of Technology and associated companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005004/en/ Picture of 1mm squared die of silicon CMOS based smell sensor, with dog nose equivalent ~1,200 sensor pixels (Photo: Business Wire) Aroma Bit: http://www.aromabit.com Realizing smartphone embeddable smell sensor with dog nose equivalent ultra-high resolution smell sensor on only 1 millimeter square silicon die size Aroma Bit has developed and are currently selling a compact smell sensor that employs QCM or Quartz Crystal Micro

Logitech Delivers a Strong Start to Fiscal Year 2020 with Robust Sales and Profit Growth23.7.2019 01:00:00 CESTPress release

Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the first quarter of Fiscal Year 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005781/en/ Logitech delivers a strong start to Fiscal Year 2020 with robust sales and profit growth. (Graphic: Business Wire) Q1 sales were $644 million, up 6 percent in US dollars and 9 percent in constant currency, compared to Q1 of the prior year. Q1 GAAP operating income grew 46 percent to $47 million, compared to $32 million in the same quarter a year ago. Q1 GAAP earnings per share (EPS) grew 17 percent to $0.27, compared to $0.23 in the same quarter a year ago. Q1 non-GAAP operating income grew 11 percent to $67 million, compared to $61 million in the same quarter a year ago. Q1 non-GAAP EPS grew 15 percent to $0.39, compared to $0.34 in the same quarter a year ago. Cash flow from operations was $37 million, compared to $12 million in the sa

Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance22.7.2019 16:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented findings from two Phase 3 trials – a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) in women, and a trial evaluating the potential for the single tablet regimen to be an effective treatment option in virologically suppressed patients with known resistance to nucleo(s)tide or non-nucleo(s)tide reverse transcriptase inhibitors (NRTIs or NNRTIs). The use of Biktarvy in patients with known drug resistance is investigational. These data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “These data presented at IAS provide new information about the treatment of HIV among women and patients with known drug resistance,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “The studies further demonstrate the potential for Biktarvy to be an